期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
原发性肝癌患者血清及肝癌组织中HBV前C区1896位突变株的研究 被引量:2
1
作者 刘宁 黄祖瑚 唐保元 《江苏医药》 CAS CSCD 1998年第12期878-880,共3页
为了解HBV前C区1896位G→A突变株和原发性肝细胞癌(HCC)的关系,采用错配引物PCR(m少PCR)扩增结合限制性片段长度多态性分析(RFLP),检测了83例HBsAg阳性HCC患者血清样本中的HBV前C区突变株,并与66份HBsAg(+)的慢性乙型肝炎... 为了解HBV前C区1896位G→A突变株和原发性肝细胞癌(HCC)的关系,采用错配引物PCR(m少PCR)扩增结合限制性片段长度多态性分析(RFLP),检测了83例HBsAg阳性HCC患者血清样本中的HBV前C区突变株,并与66份HBsAg(+)的慢性乙型肝炎患者的血清标本对照。结果发现:HCC组有47例检出HBV前C区基因(56.6%),其中16例存在HBV前C区突变株(34.0%);慢性乙肝组有33例检出HBV前C区基因(50.0%),其中仅4例存在HBV前C区突变株(12.1%),两组HBV前C区突变株检出率有显著差异(P<0.05)。为进一步研究HBV前C区突变株在HCC患者中的状况,同步检测了8例HBsAg阳性HCC患者肝癌组织和血清中HBV前C区突变株,发现在HBV前C区基因阳性的肝癌组织、癌周组织和血清中HBV前C区突变株分别为3/8(37.5%)、3/7(42.9%)和1/5(20.0%),均比慢性肝炎组高,提示HBV前C区1896位G→A突变珠在原发性肝癌的发生中可能有一定作用。 展开更多
关键词 原发性肝癌 乙肝病毒前C区突变
下载PDF
献血者中低水平HBsAg乙肝病毒感染者分子生物学特征研究 被引量:4
2
作者 许晓绚 叶贤林 +5 位作者 王霞 李彤 赵钰 李然 刘衡 曾劲峰 《中国输血杂志》 CAS 2021年第8期827-831,共5页
目的了解核酸检测初筛阴性献血者中低水平乙肝表面抗原(HBsAg)乙肝病毒(HBV)感染情况并探讨其分子生物学特征。方法从本中心2017~2018年100363(人)份无偿献血者血样中,收集HBsAg酶联免疫试验(ELISA)阳性核酸检测(NAT)阴性献血者标本,用... 目的了解核酸检测初筛阴性献血者中低水平乙肝表面抗原(HBsAg)乙肝病毒(HBV)感染情况并探讨其分子生物学特征。方法从本中心2017~2018年100363(人)份无偿献血者血样中,收集HBsAg酶联免疫试验(ELISA)阳性核酸检测(NAT)阴性献血者标本,用化学发光微粒子免疫法CMIA复检HBsAg,用电化学发光免疫法(ECLI)定量检测乙肝两对半,再做NAT单人份复检,采用巢式聚合酶链反应(PCR)扩增病毒BCP/PC和S区,用荧光定量PCR(qPCR)测定病毒载量。结果本中心2017~2018年HBV DNA(-)的低水平HBsAg献血者(标本)的检出率0.054%(60/100363),其中HBsAg ELISA试剂1检出比例90%(54/60),试剂2检出比例95%(57/60);60例中有33个可做HBV基因分型的标本,B型占87.9%(29/33),其中3.4%(1/29)为血清型ayw1、96.6%(28/29)血清型adw2;C型占12.1%(4/33),均为血清型adqr+。巢式PCR扩增:在B型S基因区发现影响HBsAg检测Q101R、Q129H、T131I、M133L/T、F134L、G145R、V168A、L175S和V177A变异株,在BCP/PC区发现减少HBV复制的高频突变C1799G(87.5%,21/24)。qPCR测得病毒载量中位数49.6(0~628)IU/ml。结论ELISA检测低水平HBsAg且NAT阴性献血者标本中存在少数未能被目前ELISA方法检出的HBV。在献血者血液筛查中应用灵敏度和特异性更高的HBsAg和NAT检测方法可提高检出HBV突变株的能力。 展开更多
关键词 乙型肝炎病毒 乙肝表面抗原 血液筛查 献血者 酶联免疫试验 核酸检测 化学发光法 病毒株突变
下载PDF
Prevalence and patterns of drug-resistance mutations among HIV-1 patients infected with CRF07_BC strains in Sichuan province,China 被引量:1
3
作者 Ling Su Xia Zhou +4 位作者 Dan Yuan Hong Yang Dongbing Wei Guangmin Qin Shu Liang 《Virologica Sinica》 SCIE CAS CSCD 2014年第4期237-241,共5页
Little information is available on the prevalence of drug-resistance mutations in patients harboring the human immunodeficiency virus type 1(HIV-1) circulating recombinant form(CRF)07_BC variant in Sichuan, China. Thi... Little information is available on the prevalence of drug-resistance mutations in patients harboring the human immunodeficiency virus type 1(HIV-1) circulating recombinant form(CRF)07_BC variant in Sichuan, China. This study examined 375 plasma samples from patients with HIV-1 who were infected with the CRF07_BC strain, including 104 drug-naive participants and 271 in whom antiretroviral therapy(ART) had failed. Only one participant in the drug-naive group had a drug-resistance mutation(M46L), compared with 31.73% of those in whom ART had failed. Further analysis showed that 19.56% of strains contained mutations conferring resistance to non-nucleoside reverse transcriptase inhibitors(NNRTIs) alone, 0.74% were resistant to nucleoside reverse transcriptase inhibitors(NRTIs) alone, and 11.44% were dual-resistant to both NRTIs and NNRTIs. The most common mutation in the ART-failure group was M184V(35.88%), K103N(45.01%), Y181C(17.33%), and G190S/A(15.88%). The percentages of HIV-1 strains resistant to lamivudine, emtricitabine, efavirenz, etravirine, and nevirapine were 10.70%, 10.70%, 28.04%, 7.75%, and 26.20%, respectively. To explore site variants possibly related to drug resistance, variations in the ancestor/consensus CRF07_BC sequences from the therapy-naive and ART-failure groups were compared, and seven mutations at six positions were identified as being significantly differently distributed between the two groups(p<0.05). Detailed sequence data will provide information on CRF07_BC genetic characterizations, and improve our understanding of antiretroviral susceptibility and the evolution of drug-resistance mutations. This will be valuable in developing and implementing local public-health approaches for HIV drug-resistance prevention and treatment. 展开更多
关键词 HIV-1 CRF07_BC drug resistance SICHUAN China
下载PDF
Critical role of Dengue Virus NS1 protein in viral replication 被引量:4
4
作者 Jingjing Fan Yi Liu Zhiming Yuan 《Virologica Sinica》 SCIE CAS CSCD 2014年第3期162-169,共8页
Dengue virus(DENV) nonstructural protein 1(NS1) is a highly conserved 46-kDa protein that contains 2 glycosylation sites(Asn-130 and Asn-207) and 12 conserved cysteine(Cys) residues. Here, we performed site-directed m... Dengue virus(DENV) nonstructural protein 1(NS1) is a highly conserved 46-kDa protein that contains 2 glycosylation sites(Asn-130 and Asn-207) and 12 conserved cysteine(Cys) residues. Here, we performed site-directed mutagenesis to generate systematic mutants of viral strain TSV01. The results of the subsequent analysis showed that an alanine substitution at the second N-linked glycan Asn-207 in NS1 delayed viral RNA synthesis, reduced virus plaque size, and weakened the cytopathic effect. Three mutants at Cys sites(Cys-4, Cys-55, Cys-291) and a C-terminal deletion(ΔC) mutant significantly impaired RNA synthesis, and consequently abolished viral growth, whereas alanine mutations at Asn-130 and Glu-173 resulted in phenotypes that were similar to the wild-type(WT) virus. Further analysis showed that the Asn-207 mutation slightly delayed viral replication. These results suggest that the three conserved disulfide bonds and the second N-linked glycan in NS1 are required for DENV-2 replication. 展开更多
关键词 dengue type 2 virus NS1 replication glycosylation site
下载PDF
Epidemiology and Mutational Analysis of Global Strains of Crimean-Congo Haemorrhagic Fever Virus
5
作者 Simon Rayner 《Virologica Sinica》 SCIE CAS CSCD 2011年第4期229-244,共16页
Crimean-Congo hemorrhagic fever (CCHF) is a severe illness with high fatality.Cases are reported in several countries in Africa,Europe,the Middle East,and Asia.Phylogenetic analyses based on the virus S (nucleocapsid)... Crimean-Congo hemorrhagic fever (CCHF) is a severe illness with high fatality.Cases are reported in several countries in Africa,Europe,the Middle East,and Asia.Phylogenetic analyses based on the virus S (nucleocapsid),M (glycoprotein),and L (polymerase) genome segments sequences indicate distinct geographic lineages exist but their specific genetic characteristics require elucidation.In this work we collected all full length S segment sequences and generated a phylogenetic tree based on the alignment of these 62 samples.We then analyzed the alignment using entries from AAIndex,the Amino Acid Index database,to identify amino acid mutations that performed significant changes in charge,pka,hydropathy and side chain volume.Finally,we mapped these changes back to the tree and alignment to identify correlated mutations or sites that characterized a specific lineage.Based on this analysis we are able to propose a number of sites that appear to be important for virus function and which would be good candidates for experimental mutational analysis studies. 展开更多
关键词 Crimean-Congo hemorrhagic fever virus (CCHFV) EPIDEMIOLOGY Mutational Analysis
下载PDF
SARS-CoV-2重组S1和S蛋白疫苗诱导保护性免疫的研究 被引量:1
6
作者 钱曼云 王继伟 +3 位作者 李颢泽 王瑞华 刘云 李亚峰 《中国生物工程杂志》 CAS CSCD 北大核心 2022年第5期106-116,共11页
目的:评价新型冠状病毒(SARS-CoV-2)重组S1蛋白和S蛋白疫苗对SARS-CoV-2的免疫保护效果。方法:将SARS-CoV-2重组S1蛋白和S蛋白分别联合氢氧化铝佐剂以0.1μg/只、1μg/只、5μg/只、10μg/只不同剂量接种6~8周BALB/c纯系健康雌性小鼠。... 目的:评价新型冠状病毒(SARS-CoV-2)重组S1蛋白和S蛋白疫苗对SARS-CoV-2的免疫保护效果。方法:将SARS-CoV-2重组S1蛋白和S蛋白分别联合氢氧化铝佐剂以0.1μg/只、1μg/只、5μg/只、10μg/只不同剂量接种6~8周BALB/c纯系健康雌性小鼠。第二次免疫后采血通过酶联免疫吸附试验(ELISA)检测血清中IgG抗体效价,通过假病毒中和试验比较免疫小鼠血清对SARS-CoV-2野生型株(WT)、英国株(B.1.1.7)、巴西株(P.1)、印度株(B.1.617.2)、Mu毒株(B.1.621)和南非株(501Y.V2-1)六种假病毒毒株中和活性效价,取脾细胞通过酶联免疫斑点技术(ELISpot)检测免疫小鼠的细胞免疫水平。结果:SARS-CoV-2重组S和S1蛋白都能诱导小鼠产生较强的IgG抗体水平。免疫S1蛋白的小鼠血清对SARS-CoV-2野生型株、英国株、巴西株有明显的中和活性,免疫S蛋白的小鼠血清除了对SARS-CoV-2野生型株、英国株、巴西株有明显中和活性之外,对印度株也有明显的中和活性,两种蛋白质免疫的小鼠血清均对野生型株中和效果最强。S蛋白免疫的小鼠脾细胞能够显著诱导出γ干扰素(IFN-γ)和白介素-4(IL-4)的产生。S蛋白诱导产生的IgG抗体、中和抗体、细胞免疫水平均高于S1。结论:SARS-CoV-2重组S蛋白疫苗能够诱导产生较强的保护性免疫应答。 展开更多
关键词 新型冠状病毒 S蛋白 S1蛋白 新型冠状病毒突变 保护性免疫应答
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部